MedPath

A DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, ESCALATING MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF TV-1380 IN HEALTHY VOLUNTEERS

Completed
Conditions
Cocaineverslaving en cocaine-overdosis
Cocaine addiction
Registration Number
NL-OMON35366
Lead Sponsor
TEVA Pharma
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
33
Inclusion Criteria

Healthy male and female volunteers, 18-45 years of age, BMI between 18.0 and 30.0 kg/m2; weight is at least 50 kg, no smokers for at least 3 months

Exclusion Criteria

Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 90 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath